Status
Conditions
Treatments
About
Pediatric acute respiratory distress syndrome (PARDS) is a severe and diffuse lung injury that is a common cause of admission and mortality in the pediatric intensive care unit (PICU). PARDS can be secondary to many different causes, and there are few therapies that have been shown beneficial in PARDS. This study seeks to identify important PARDS subtypes using gene expression profiling of bronchial epithelial cells from control and PARDS subjects.
Full description
Enrolled subjects will have nasal brushings collected at days 1, 3, 7, and 14 of intubation with collection of serum at these same time points. Brushing RNA will be processed by mRNA-Seq for gene expression analysis and compared to previously published serum biomarkers (interleukin-8, advanced glycosylation end-product specific receptor, and angiopoietin-2) to assess correlation and ability to discriminate PARDS endotypes. Changes in gene expression over time will be assessed to define a PARDS recovery gene expression signature, and correlation between bronchial and nasal gene expression will be determined.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
All potential participants must:
ARDS patients must:
Have acute changes in chest x-ray (CXR)
Have a known or suspected insult within the prior 7 days that is consistent with ARDS
Have an oxygenation index (OI) of 4 or greater or and oxygen-sat index (OSI) of 5 or greater
Exclusion criteria
76 participants in 2 patient groups
Loading...
Central trial contact
Rhonda Jones, RN; Toni Yunger
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal